Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma
Clinical Cancer Research2022Vol. 28(12), pp. 2567–2578
Citations Over TimeTop 10% of 2022 papers
Lakshmi Nayak, Nathan Standifer, Jörg Dietrich, Jennifer Clarke, Gavin P. Dunn, Michael Lim, Timothy F. Cloughesy, Hui Gan, Elizabeth Flagg, Elizabeth George, Sarah Gaffey, Julia Hayden, Christina Holcroft, Patrick Y. Wen, Mary Macri, Andrew Park, Toni Ricciardi, Aileen Ryan, Paul Schwarzenberger, Ralph Venhaus, Melissa de los Reyes, Nicholas M. Durham, Todd Creasy, Raymond Y. Huang, Thomas Kaley, David A. Reardon
Abstract
Patients with recurrent glioblastoma have markedly lower baseline levels of multiple circulating immune cell subsets compared with newly diagnosed patients. An early increase in systemic Ki67+CD8+ cells may warrant further evaluation as a potential biomarker of therapeutic benefit among patients with glioblastoma undergoing checkpoint therapy. Dexamethasone decreased immune cell subsets. PD-L1 blockade and combination with standard or reduced dose bevacizumab was ineffective.
Related Papers
- → Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status(2015)19 cited
- → Durvalumab (Imfinzi™)(2017)4 cited
- → Durvalumab Immunotherapy: Nursing Management of Immune-Related Adverse Events During the Journey of Patients With Stage III Non-Small Cell Lung Cancer(2020)2 cited
- → Durvalumab for the treatment of PD-L1 non-small cell lung cancer(2020)1 cited
- → P21.09 Does Duration of Maintenance Durvalumab Matter? Relationship between Length of Durvalumab Therapy and PFS.(2021)